Top

BMC Psychiatry

Published in:

Open Access 01-12-2024 | Ketamine | Case Report

Ketamine cystitis following ketamine therapy for treatment-resistant depression – case report

Authors: Minna Chang, Mario F Juruena, Allan H Young

Published in: BMC Psychiatry | Issue 1/2024

Abstract

Background

Ketamine is a novel and exciting putative antidepressant medication for patients with treatment-resistant depression. A complication commonly seen in frequent and heavy recreational use of ketamine is ulcerative cystitis, which presents with lower urinary tract symptoms (LUTS) and upper renal tract damage and can be seen in over 25% of regular users. Although Ketamine-induced cystitis (KIC) is a recognised complication in recreational use of ketamine, its occurrence in therapeutic use of ketamine in depression has so far not been reported. The exact pathogenesis of KIC is currently unknown, making treatment and prevention advice much more difficult. Early diagnosis of KIC and immediate cessation of ketamine has been shown to improve adverse urinary tract symptoms and prevent further damage.

Case presentation

We present a case of a 28-year-old female who was started on ketamine treatment for depression, and who then developed symptoms of KIC, which was confirmed by urine microscopy, culture and analysis.

Conclusions

To our knowledge, this is the first reported case of KIC in a patient receiving treatment-dose ketamine as part of their antidepressant therapy.

Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A Randomized Trial of an N-methyl-D-aspartate antagonist in treatment-resistant Major Depression. Archives of General Psychiatry [online]. 2006;63(8):856. https://doi.org/10.1001/archpsyc.63.8.856.CrossRefPubMed

Bahji A, Vazquez GH, Zarate CA. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2020;278:12473. https://doi.org/10.1016/j.jad.2020.09.071.CrossRef

Winstock AR, Mitcheson L, Gillatt DA, Cottrell AM. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int. 2012;110(11):1762–6. https://doi.org/10.1111/j.1464-410x.2012.11028.x.CrossRefPubMed

Huang Y-C, Jeng C-M, Cheng T-C. Ketamine-associated Ulcerative Cystitis. Tzu Chi Medical Journal. 2008;20(2):144–6. https://doi.org/10.1016/s1016-3190(08)60026-9.CrossRef

Yek J, Sundaram P, Aydin H, Kuo T, Ng L. The clinical presentation and diagnosis of ketamine-associated urinary tract dysfunction in Singapore. Singapore Med J. 2015;56(12):660–5. https://doi.org/10.11622/smedj.2015185.CrossRefPubMedPubMedCentral

Anderson DJ, Zhou J, Cao D, McDonald M, Guenther M, Hasoon J, Viswanath O, Kaye AD, Urits I. (2022). Ketamine-Induced Cystitis: A Comprehensive Review of the Urologic Effects of This Psychoactive Drug. Health Psychology Research, [online] 10(3). https://doi.org/10.52965/001c.38247.

Charlson F, van Ommeren M, Flaxman A, Cornett J, Whiteford H, Saxena S. (2019). New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis. The Lancet, [online] 394(10194), pp.240–248. https://doi.org/10.1016/s0140-6736(19)30934-1.

Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a Randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–38. https://doi.org/10.1176/appi.ajp.2019.19020172.CrossRefPubMed

Hentzen C, Panicker JN, Pericolini M, Finazzi Agrò E, Chesnel C, Blouet E, Le Breton F, Sheikh Ismaël S, Haddad R, Amarenco G. Persistent need to urinate: a common sensory symptom leading to urinary discomfort. A study of 79 cases. Cont Rep. 2022;2:100007. https://doi.org/10.1016/j.contre.2022.100007.CrossRef

10.

Yee C-H, Teoh JY-C, Lai P-T, Leung VY-F, Chu WC-W, Lee W, Tam Y-H, Ng C-F. The risk of Upper urinary tract involvement in patients with ketamine-Associated Uropathy. Int Neurourol J. 2017;21(2):128–32. https://doi.org/10.5213/inj.1732704.352.CrossRefPubMedPubMedCentral

11.

Zhou J, Scott C, Miab ZR, Lehmann C. Current approaches for the treatment of ketamine-induced cystitis. Neurourol Urodyn. 2023. https://doi.org/10.1002/nau.25148.CrossRefPubMed

12.

Lee W-C, Su C-H, Tain Y-L, Tsai C-N, Yu C-C, Chuang Y-C. Potential Orphan Drug Therapy of Intravesical Liposomal Onabotulinumtoxin-A for ketamine-Induced Cystitis by Mucosal Protection and anti-inflammation in a rat model. Sci Rep [online]. 2018;8(1). https://doi.org/10.1038/s41598-018-24239-9.

13.

Zaki N, Chen L, Lane R, Doherty T, Drevets WC, Morrison RL, Sanacora G, Wilkinson ST, Popova V, Fu D. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology. 2023;48(8):1225–33. https://doi.org/10.1038/s41386-023-01577-5.CrossRefPubMedPubMedCentral

14.

Wajs E, Aluisio L, Holder R, Daly E, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JH, Manji HK, Hough D, Grunfeld J, Jeon HJ, Wilkinson ST, Singh J. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: Assessment of Long-Term Safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020;81(3). https://doi.org/10.4088/jcp.19m12891.

15.

Daly E, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca A, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubała WJ, Bitter I, Blier P, Shelton RC, Singh J. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression. JAMA Psychiatry. 2019;76(9):893. https://doi.org/10.1001/jamapsychiatry.2019.1189.CrossRefPubMedPubMedCentral

16.

Spravato 28 mg nasal. spray, solution - Summary of Product Characteristics (SmPC) (emc). www.medicines.org.uk. https://www.medicines.org.uk/emc/product/10977/smpc#gref.

17.

Findeis H, Sauer C, Cleare AJ, Bauer M, Ritter P. Urothelial toxicity of esketamine in the treatment of depression. Psychopharmacology. 2020;237(11):3295–302. https://doi.org/10.1007/s00213-020-05611-y.CrossRefPubMedPubMedCentral

Title: Ketamine cystitis following ketamine therapy for treatment-resistant depression – case report
Authors: Minna Chang
Mario F Juruena
Allan H Young
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Ketamine
Cystitis
Cystitis
Mood Disorders
Affective Disorder
Antidepressant Drugs
Antidepressant Drugs
Esketamine
Esketamin
Published in: BMC Psychiatry / Issue 1/2024
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-023-05468-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ketamine cystitis following ketamine therapy for treatment-resistant depression – case report

Abstract

Background

Case presentation

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

“Anxiety is not cute” analysis of twitter users’ discourses on romanticizing mental illness

Monthly engagement with EIP keyworkers was associated with a five-fold increase in the odds of engagement with psychosocial interventions

The mediating role of sleep problems and depressed mood between psychological abuse/neglect and suicidal ideation in adolescent childhood: a multicentred, large sample survey in Western China

Decomposing the rural–urban differences in depression among multimorbid older patients in India: evidence from a cross-sectional study

The relationship between academic stress and depression among college students during the COVID-19 pandemic: a cross-sectional study from China

Effects of yoga on impulsivity in patients with and without mental disorders: a systematic review